NCT06986603View on ClinicalTrials.gov

Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia

PHASE4RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

September 1, 2026

Conditions
HypoglycemiaHypoglycemia, ReactiveBariatric Surgery
Interventions
DRUG

Glucagon for Injection (Fresenius Kabi USA)

We are assessing response to glucose, including incremental glucose values as well as changes in endogenous glucose production, insulin secretion, and glucagon levels.

Trial Locations (2)

35233

RECRUITING

University of Alabama, Birmingham

02215

RECRUITING

Joslin Diabetes Center, Boston

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

University of Virginia

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Joslin Diabetes Center

OTHER